• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分析 Caco-2 细胞中特定于 KRAS 效应因子(亚)复合物的情况。

Analysis of context-specific KRAS-effector (sub)complexes in Caco-2 cells.

机构信息

Systems Biology Ireland, School of Medicine, University College Dublin, Dublin 4, Ireland.

UCD Charles Institute of Dermatology, School of Medicine, University College Dublin, Dublin 4, Ireland.

出版信息

Life Sci Alliance. 2023 Mar 9;6(5). doi: 10.26508/lsa.202201670. Print 2023 May.

DOI:10.26508/lsa.202201670
PMID:36894174
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9998658/
Abstract

Ras is a key switch controlling cell behavior. In the GTP-bound form, Ras interacts with numerous effectors in a mutually exclusive manner, where individual Ras-effectors are likely part of larger cellular (sub)complexes. The molecular details of these (sub)complexes and their alteration in specific contexts are not understood. Focusing on KRAS, we performed affinity purification (AP)-mass spectrometry (MS) experiments of exogenously expressed FLAG-KRAS WT and three oncogenic mutants ("genetic contexts") in the human Caco-2 cell line, each exposed to 11 different culture media ("culture contexts") that mimic conditions relevant in the colon and colorectal cancer. We identified four effectors present in complex with KRAS in all genetic and growth contexts ("context-general effectors"). Seven effectors are found in KRAS complexes in only some contexts ("context-specific effectors"). Analyzing all interactors in complex with KRAS per condition, we find that the culture contexts had a larger impact on interaction rewiring than genetic contexts. We investigated how changes in the interactome impact functional outcomes and created a Shiny app for interactive visualization. We validated some of the functional differences in metabolism and proliferation. Finally, we used networks to evaluate how KRAS-effectors are involved in the modulation of functions by random walk analyses of effector-mediated (sub)complexes. Altogether, our work shows the impact of environmental contexts on network rewiring, which provides insights into tissue-specific signaling mechanisms. This may also explain why KRAS oncogenic mutants may be causing cancer only in specific tissues despite KRAS being expressed in most cells and tissues.

摘要

Ras 是一个控制细胞行为的关键开关。在 GTP 结合形式下,Ras 以相互排斥的方式与众多效应物相互作用,其中单个 Ras 效应物可能是更大细胞(亚)复合物的一部分。这些(亚)复合物的分子细节及其在特定环境下的改变尚不清楚。我们专注于 KRAS,在人类 Caco-2 细胞系中,对外源性表达的 FLAG-KRAS WT 和三种致癌突变体(“遗传背景”)进行了亲和纯化(AP)-质谱(MS)实验,每种突变体都暴露于 11 种不同的培养基(“培养背景”)中,这些培养基模拟了在结肠和结直肠癌中相关的条件。我们鉴定了在所有遗传和生长背景下与 KRAS 复合物存在的四个效应物(“背景通用效应物”)。只有在某些背景下才能在 KRAS 复合物中发现七个效应物(“背景特异效应物”)。分析每种条件下与 KRAS 相互作用的所有相互作用蛋白,我们发现培养背景对相互作用重排的影响大于遗传背景。我们研究了互作组的变化如何影响功能结果,并创建了一个用于交互式可视化的 Shiny 应用程序。我们验证了一些代谢和增殖方面的功能差异。最后,我们使用网络来评估 KRAS-效应物如何通过效应物介导的(亚)复合物的随机游走分析参与功能的调节。总之,我们的工作表明环境背景对网络重排的影响,这为组织特异性信号机制提供了深入的了解。这也可能解释了为什么 KRAS 致癌突变体仅在特定组织中引起癌症,尽管 KRAS 在大多数细胞和组织中都有表达。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/bc84e2cf47be/LSA-2022-01670_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/933d8aaf15d0/LSA-2022-01670_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/f57bfbca69c2/LSA-2022-01670_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/8fd58a4616af/LSA-2022-01670_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/5dc6d1496a32/LSA-2022-01670_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/3e42375e7888/LSA-2022-01670_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/30c298e4a91b/LSA-2022-01670_FigS5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/f63cf7bfb780/LSA-2022-01670_FigS6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/2c0e6e5d3ff4/LSA-2022-01670_FigS7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/f609a0cd7478/LSA-2022-01670_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/8fbeb0c3da77/LSA-2022-01670_FigS8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/d5ef24edccca/LSA-2022-01670_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/1bf7e356789d/LSA-2022-01670_FigS9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/b2b1607fb0b5/LSA-2022-01670_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/491028108dbc/LSA-2022-01670_FigS10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/157e9424d5a8/LSA-2022-01670_FigS11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/9433ef2bae7a/LSA-2022-01670_FigS12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/75b5d414d3f6/LSA-2022-01670_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/ffd39dd61fe2/LSA-2022-01670_FigS13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/0e9afb564364/LSA-2022-01670_FigS14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/bc84e2cf47be/LSA-2022-01670_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/933d8aaf15d0/LSA-2022-01670_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/f57bfbca69c2/LSA-2022-01670_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/8fd58a4616af/LSA-2022-01670_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/5dc6d1496a32/LSA-2022-01670_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/3e42375e7888/LSA-2022-01670_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/30c298e4a91b/LSA-2022-01670_FigS5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/f63cf7bfb780/LSA-2022-01670_FigS6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/2c0e6e5d3ff4/LSA-2022-01670_FigS7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/f609a0cd7478/LSA-2022-01670_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/8fbeb0c3da77/LSA-2022-01670_FigS8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/d5ef24edccca/LSA-2022-01670_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/1bf7e356789d/LSA-2022-01670_FigS9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/b2b1607fb0b5/LSA-2022-01670_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/491028108dbc/LSA-2022-01670_FigS10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/157e9424d5a8/LSA-2022-01670_FigS11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/9433ef2bae7a/LSA-2022-01670_FigS12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/75b5d414d3f6/LSA-2022-01670_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/ffd39dd61fe2/LSA-2022-01670_FigS13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/0e9afb564364/LSA-2022-01670_FigS14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae20/9998658/bc84e2cf47be/LSA-2022-01670_Fig6.jpg

相似文献

1
Analysis of context-specific KRAS-effector (sub)complexes in Caco-2 cells.分析 Caco-2 细胞中特定于 KRAS 效应因子(亚)复合物的情况。
Life Sci Alliance. 2023 Mar 9;6(5). doi: 10.26508/lsa.202201670. Print 2023 May.
2
Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.致癌性 KRAS 通过 RSK1/NF1 途径抑制胰腺癌中的野生型 RAS 信号。
Proc Natl Acad Sci U S A. 2021 May 25;118(21). doi: 10.1073/pnas.2016904118.
3
Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.非经典和新型结直肠癌 KRAS 和 NRAS 突变体的非冗余和重叠致癌读出。
Cells. 2019 Dec 3;8(12):1557. doi: 10.3390/cells8121557.
4
Structures of RGL1 RAS-Association Domain in Complex with KRAS and the Oncogenic G12V Mutant.与KRAS及致癌性G12V突变体结合的RGL1 RAS关联结构域的结构
J Mol Biol. 2022 May 15;434(9):167527. doi: 10.1016/j.jmb.2022.167527. Epub 2022 Mar 4.
5
Dual role of sprouty2 as an inhibitor of RAS/ERK-driven proliferation and a promoter of cancer invasion in KRAS wild-type colorectal cancer.Sprouty2 在 KRAS 野生型结直肠癌中作为 RAS/ERK 驱动的增殖抑制剂和癌症侵袭促进剂的双重作用。
Mol Carcinog. 2023 Jul;62(7):951-962. doi: 10.1002/mc.23537. Epub 2023 Apr 4.
6
Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.KRAS/PAK1/Crk通路在非小细胞肺癌发生中的意义。
BMC Cancer. 2015 May 9;15:381. doi: 10.1186/s12885-015-1360-4.
7
Insights into the Cross Talk between Effector and Allosteric Lobes of KRAS from Methyl Conformational Dynamics.从甲基构象动力学看 KRAS 效应结构域和变构结构域的串扰。
J Am Chem Soc. 2022 Mar 9;144(9):4196-4205. doi: 10.1021/jacs.2c00007. Epub 2022 Feb 25.
8
Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.Ras效应器突变体表达提示一种负调节因子抑制肺肿瘤形成。
PLoS One. 2014 Jan 28;9(1):e84745. doi: 10.1371/journal.pone.0084745. eCollection 2014.
9
Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers.绘制KRAS驱动癌症中的效应器-表型图谱
Trends Cancer. 2018 May;4(5):333-335. doi: 10.1016/j.trecan.2018.02.004. Epub 2018 Mar 7.
10
KRAS Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer.在非小细胞肺癌中,KRAS 以 RAF 二聚体依赖的方式优先通过 MAPK 信号传导。
Cancer Res. 2020 Sep 1;80(17):3719-3731. doi: 10.1158/0008-5472.CAN-20-0448. Epub 2020 Jun 30.

引用本文的文献

1
Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity.通过对映体差异活性研究胰腺癌中的合成致死性和PARP抑制剂耐药性。
Cell Death Discov. 2025 Mar 16;11(1):106. doi: 10.1038/s41420-025-02382-3.
2
Feature Selection and Network-Driven Analyses to Unveil Common RNA Signatures in Colon and Pancreatic KRAS-Mutant Cancers.特征选择与网络驱动分析以揭示结肠和胰腺KRAS突变癌中的常见RNA特征
Cancer Med. 2025 Mar;14(5):e70468. doi: 10.1002/cam4.70468.
3
Functional and structural insights into RAS effector proteins.

本文引用的文献

1
Control of cell state transitions.细胞状态转变的控制。
Nature. 2022 Sep;609(7929):975-985. doi: 10.1038/s41586-022-05194-y. Epub 2022 Sep 14.
2
simplifyEnrichment: A Bioconductor Package for Clustering and Visualizing Functional Enrichment Results.simplifyEnrichment:一个用于聚类和可视化功能富集结果的 Bioconductor 包。
Genomics Proteomics Bioinformatics. 2023 Feb;21(1):190-202. doi: 10.1016/j.gpb.2022.04.008. Epub 2022 Jun 6.
3
Differential impact of lipid raft depletion on platelet-derived growth factor (PDGF)-induced ERK1/2 MAP-kinase, SRC and AKT signaling.
RAS 效应蛋白的功能和结构见解。
Mol Cell. 2024 Aug 8;84(15):2807-2821. doi: 10.1016/j.molcel.2024.06.027. Epub 2024 Jul 17.
4
Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib.KRAS 突变体相互作用组的蛋白质组学图谱揭示了 RAS 信号网络的新特征及索托拉西布的作用机制。
Cancers (Basel). 2023 Aug 17;15(16):4141. doi: 10.3390/cancers15164141.
5
Dynamic regulation of RAS and RAS signaling.RAS 及其信号通路的动态调控。
Biochem J. 2023 Jan 13;480(1):1-23. doi: 10.1042/BCJ20220234.
脂筏耗竭对血小板衍生生长因子(PDGF)诱导的 ERK1/2 MAP 激酶、SRC 和 AKT 信号的差异影响。
Cell Signal. 2022 Aug;96:110356. doi: 10.1016/j.cellsig.2022.110356. Epub 2022 May 20.
4
Reconstruction and analysis of a large-scale binary Ras-effector signaling network.重建和分析大规模的二元 Ras 效应子信号网络。
Cell Commun Signal. 2022 Mar 4;20(1):24. doi: 10.1186/s12964-022-00823-5.
5
A Modular and Expandable Ecosystem for Metabolomics Data Annotation in R.R语言中用于代谢组学数据注释的模块化可扩展生态系统。
Metabolites. 2022 Feb 11;12(2):173. doi: 10.3390/metabo12020173.
6
Network pharmacology: curing causal mechanisms instead of treating symptoms.网络药理学:从病因机制治疗,而非对症治疗。
Trends Pharmacol Sci. 2022 Feb;43(2):136-150. doi: 10.1016/j.tips.2021.11.004. Epub 2021 Dec 9.
7
Make Interactive Complex Heatmaps in R.在 R 中制作交互式复杂热图。
Bioinformatics. 2022 Feb 7;38(5):1460-1462. doi: 10.1093/bioinformatics/btab806.
8
The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences.PRIDE 数据库资源在 2022 年:一个基于质谱的蛋白质组学证据的中心。
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552. doi: 10.1093/nar/gkab1038.
9
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data.clusterProfiler 4.0:用于解释组学数据的通用富集工具。
Innovation (Camb). 2021 Jul 1;2(3):100141. doi: 10.1016/j.xinn.2021.100141. eCollection 2021 Aug 28.
10
Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.双重蛋白质组尺度网络揭示了人类相互作用组的细胞特异性重塑。
Cell. 2021 May 27;184(11):3022-3040.e28. doi: 10.1016/j.cell.2021.04.011. Epub 2021 May 6.